In vitro methods for diagnosing nonimmediate hypersensitivity reactions to drugs

Journal of Investigational Allergology and Clinical Immunology

Volumn 23, Issue 4, 2013, Pages 213-225

  Mayorga, C ^a   Sanz, M L ^b   Gamboa, P ^c   Garcia Aviles, M C ^d   Fernandez, J ^e   Torres, Maria José ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c HOSPITAL DE BASURTO   (Spain)

^d Hospital Moncloa   (Spain)

^e Alicante General Hospital   (Spain)

Author keywords

Diagnosis; Drug hypersensitivity; In vitro; Lymphocyte; Nonimmediate

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BIOLOGICAL MARKER; CARBAMAZEPINE; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CD4 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; CEPHALOSPORIN; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR6; CUTANEOUS T CELL ATTRACTING CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; GRANULYSIN; GRANZYME B; IMMUNOGLOBULIN E; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; METHOTREXATE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PERFORIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ACUTE PHASE RESPONSE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN DETECTION; ANTIGEN PRESENTING CELL; BLOOD ANALYSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELL MIGRATION; CELLULAR IMMUNITY; CLINICAL FEATURE; CONTACT DERMATITIS; CROSS REACTION; CUTANEOUS PARAMETERS; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DISEASE COURSE; DRESS SYNDROME; DRUG HYPERSENSITIVITY; DRUG INDUCED ALLERGIC HEPATITIS; DRUG INDUCED EOSINOPHILIC INTERSTITIAL LUNG DISEASE; DRUG METABOLISM; ENZYME LINKED IMMUNOSPOT ASSAY; EOSINOPHILIA; ERYTHEMA MULTIFORME; FIXED DRUG ERUPTION; FLOW CYTOMETRY; GLOMERULONEPHRITIS; HEMOLYTIC ANEMIA; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOCYTOCHEMISTRY; IMMUNOLOGICAL MONITORING; IMMUNOLOGICAL PROCEDURES; IMMUNOSTIMULATION; IN VITRO DIAGNOSTIC TEST; INTERSTITIAL LUNG DISEASE; INTERSTITIAL NEPHRITIS; INTRACUTANEOUS TEST; LOEFFLER PNEUMONIA; LUNG FIBROSIS; LUNG INFILTRATE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTE TRANSFORMATION TEST; MACULOPAPULAR RASH; MEDICAL HISTORY; NATURAL KILLER CELL; NEPHROTIC SYNDROME; NONIMMEDIATE DRUG HYPERSENSITIVITY REACTION; PATCH TEST; PNEUMONIA; PRACTICE GUIDELINE; PROTEIN EXPRESSION; PROVOCATION TEST; REVIEW; SENSITIVITY AND SPECIFICITY; SERUM SICKNESS; SKIN BIOPSY; SKIN TEST; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE; TH1 CELL; TH2 CELL; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS; URTICARIA;

ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; BIOLOGICAL MARKERS; DRUG HYPERSENSITIVITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOGLOBULIN E; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; REAL-TIME POLYMERASE CHAIN REACTION; SKIN; SKIN TESTS; T-LYMPHOCYTES;

EID: 84879441138     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. Rawlins MD, Thompson JW. Mechanisms of adverse drug reactions. In: Davies DM, editor. Textbook of adverse drug reactions. Oxford University Press; 1991: Oxford.
2. Johansson SG, Hourihane JO, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T, Kowalski ML, Mygind N, Ring J, van Cauwenberge P, van Hage-Hamsten M, Wuthrich Bforce Ent. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy. 2001;56(9):813-24.
3. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med. 2003;139(8):683-93.
4. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, Motala C, Ortega Martell JA, Platts-Mills TA, Ring J, Thien F, Van Cauwenberge PWilliams HC. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113(5):832-6.
5. Harboe T, Johansson SG, Florvaag E, Oman H. Pholcodine exposure raises serum IgE in patients with previous anaphylaxis to neuromuscular blocking agents. Allergy. 2007; 62(12): 1445-50.
6. Levine BB. Immunologic mechanisms of penicillin allergy. A haptenic model system for the study of allergic diseases of man. N Engl J Med. 1966;275(20):1115-25.
7. Torres MJ, Blanca M, Fernandez J, Romano A, Weck A, Aberer W, Brockow K, Pichler WJ, Demoly P; ENDA; EAACI Interest Group on Drug Hypersensitivity. Diagnosis of immediate allergic reactions to beta-lactam antibiotics. Allergy. 2003;58(10):961-72.
8. Romano A, Blanca M, Torres MJ, Bircher A, Aberer W, Brockow K, Pichler WJ, Demoly P; ENDA, EAACI. Diagnosis of nonimmediate reactions to beta-lactam antibiotics. Allergy. 2004;59(11):1153-60.
9. Blanca M, Romano A, Torres MJ, Fernandez J, Mayorga C, Rodriguez J, Demoly P, Bousquet PJ, Merk HF, Sanz ML, Ott H, Atanaskovic-Markovic M. Update on the evaluation of hypersensitivity reactions to betalactams. Allergy. 2009;64(2):183-93.
10. Romano A, Torres MJ, Castells M, Sanz ML, Blanca M. Diagnosis and management of drug hypersensitivity reactions. J Allergy Clin Immunol. 2011;127(3 Suppl):S67-73.
11. Bircher AJ, Scherer Hofmeier K. Drug hypersensitivity reactions: Inconsistency in the use of the classification of immediate and nonimmediate reactions. J Allergy Clin Immunol. 2012;129(1):263-4; author reply 265-6.
12. Romano A, Torres MJ, Castells M, Sanz ML, Blanca M. Reply to: Drug hypersensitivity reactions: Inconsistency in the use of the classification of immediate and nonimmediate reactions. J Allergy Clin Immunol. 2012;129(1):265-6.
13. Cornejo-Garcia JA, Blanca-Lopez N, Dona I, Andreu I, Agundez JA, Carballo M, Blanca M, Canto MG. Hypersensitivity reactions to non-steroidal anti-inflammatory drugs. Curr Drug Metab. 2009;10(9):971-80.
14. Demoly P, Viola M, Rebelo-Gomes E, Romano A. Epidemiology and causes of drug hypersensitivity. In, WJ Pichler, editors. Drug Hypersensitivity Karger; 2007: Basel.
15. Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy. 2002;57(1):45-51.
16. Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J, Brockow K, Pichler WJ, Demoly P, European Network for Drug Allergy (ENDA); EAACI Interest group on drug hypersensitivity. Drug provocation testing in the diagnosisof drug hypersensitivity reactions: general considerations. Allergy. 2003;58(9):854-63.
17. Seitz CS, Brocker EB, Trautmann A. Diagnostic testing in suspected fluoroquinolone hypersensitivity. Clin Exp Allergy. 2009;39(11):1738-45.
18. Caubet JC, Kaiser L, Lemaitre B, Fellay B, Gervaix A, Eigenmann PA. The role of penicillin in benign skin rashes in childhood: a prospective study based on drug rechallenge. J Allergy Clin Immunol. 2011;127(1):218-22.
19. Padial A, Antunez C, Blanca-López N, Fernández TD, Cornejo-García JA, Mayorga C, Torres MJ, Blanca M. Non-immediate reactions to beta-lactams: diagnostic value of skin testing and drug provocation test. Clin Exp Allergy. 2008;38(5):822-8.
20. Blanca-López N, Zapatero L, Alonso E, Torres MJ, Fuentes V, Martínez-Molero MI, Blanca M. Skin testing and drug provocation in the diagnosis of nonimmediate reactions to aminopenicillins in children. Allergy. 2009;64(2):229-33.
21. Bircher AJ. Approach to the patient with a drug hypersensitivity reaction. Clinical perspectives. In: Pichler WJ, editor. Drug Hypersensitivity. Karger; 2007: Basel.
22. Nigen S, Knowles SR, Shear NH. Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J Drugs Dermatol. 2003;2(3):278-99.
23. Fernandez TD, Canto G, Blanca M. Molecular mechanisms of maculopapular exanthema. Curr Opin Infect Dis. 2009;22(3):272-8.
24. Metz M, Maurer M. Innate immunity and allergy in the skin. Curr Opin Immunol. 2009;21(6):687-93.
25. Blanca M, Posadas S, Torres MJ, Leyva L, Mayorga C, González L, Juárez C, Fernández J, Santamaria LF. Expression of the skin-homing receptor in peripheral blood lymphocytes from subjects with nonimmediate cutaneous allergic drug reactions. Allergy. 2000;55(11):998-1004.
26. Ramírez-González MD, Herrera-Enríquez M, Villanueva-Rodríguez LG, Castell-Rodríguez AE. Role of epidermal dendritic cells in drug-induced cutaneous adverse reactions. Handb Exp Pharmacol. 2009;(188):137-62.
27. Bos JD, Kapsenberg ML. The skin immune system: progress in cutaneous biology. Immunol Today. 1993;14(2):75-8.
28. Naisbitt DJ, Pirmohamed M, Park BK. Immunological principles of T-cell-mediated adverse drug reactions in skin. Expert Opin Drug Saf. 2007;6(2):109-24.
29. Naisbitt DJ, Williams DP, Pirmohamed M, Kitteringham NR, Park BK. Reactive metabolites and their role in drug reactions. Curr Opin Allergy Clin Immunol. 2001;1(4):317-25.
30. Sanderson JP, Naisbitt DJ, Park BK. Role of bioactivation in drug-induced hypersensitivity reactions. AAPS J. 2006;8(1):E55-64.
31. Williams DP, Naisbitt DJ. Toxicophores: groups and metabolic routes associated with increased safety risk. Curr Opin Drug Discov Devel. 2002;5(1):104-15.
32. Park BK, Pirmohamed M, Kitteringham NR. The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol Ther. 1995;68(3):385-424.
33. Kalgutkar AS, Obach RS, Maurer TS. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. Curr Drug Metab. 2007;8(5):407-47.
34. Baron JM, Holler D, Schiffer R, Frankenberg S, Neis M, Merk HF, Jugert FK. Expression of multiple cytochrome p450 enzymes and multidrug resistance-associated transport proteins in human skin keratinocytes. J Invest Dermatol. 2001;116(4):541-8.
35. Saeki M, Saito Y, Nagano M, Teshima R, Ozawa S, Sawada J. mRNA expression of multiple cytochrome p450 isozymes in four types of cultured skin cells. Int Arch Allergy Immunol. 2002;127(4):333-6.
36. Uetrecht J. Evaluation of which reactive metabolite, if any, is responsible for a specific idiosyncratic reaction. Drug Metab Rev. 2006;38(4):745-53.
37. Uetrecht J. Role of drug metabolism for breaking tolerance and the localization of drug hypersensitivity. Toxicology. 2005;209(2):113-8.
38. Cornejo-García JA, Fernández TD, Torres MJ, Carballo M, Hernan I, Antúnez C, Blanca M, Mayorga C. Differential cytokine and transcription factor expression in patients with allergic reactions to drugs. Allergy. 2007;62(12):1429-38.
39. Posadas SJ, Leyva L, Torres MJ, Rodríguez JL, Bravo I, Rosal M, Fernández J, Juárez C, Blanca M. Subjects with allergic reactions to drugs show in vivo polarized patterns of cytokine expression depending on the chronology of the clinical reaction. J Allergy Clin Immunol. 2000;106(4):769-76.
40. Mauri-Hellweg D, Bettens F, Mauri D, Brander C, Hunziker T, Pichler WJ. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J Immunol. 1995;155(1):462-72.
41. Schnyder B, Burkhart C, Schnyder-Frutig K, von Greyerz S, Naisbitt DJ, Pirmohamed M, Park BK, Pichler WJ. Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. J Immunol. 2000;164(12):6647-54.
42. Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, Chin SW, Chiou CC, Chu SC, Ho HC, Yang CH, Lu CF, Wu JY, Liao YD, Chen YT. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14(12):1343-50.
43. Nassif A, Bensussan A, Boumsell L, Deniaud A, Moslehi H, Wolkenstein P, Bagot M, Roujeau JC. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol. 2004;114(5):1209-15.
44. Nassif A, Bensussan A, Dorothee G, Mami-Chouaib F, Bachot N, Bagot M, Boumsell L, Roujeau JC. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol. 2002;118(4):728-33.
45. Torres MJ, Mayorga C, Fernández TD, Cornejo-García JA, Antúnez C, Valenzuela M, Del Prado MF, Rodríguez-Pena R, Blanca M. T cell assessment in allergic drug reactions during the acute phase according to the time of occurrence. Int J Immunopathol Pharmacol. 2006;19(1):119-30.
46. Rozieres A, Vocanson M, Said BB, Nosbaum A, Nicolas JF. Role of T cells in nonimmediate allergic drug reactions. Curr Opin Allergy Clin Immunol. 2009;9(4):305-10.
47. Mayorga C, Torres MJ, Corzo JL, Sanchez-Sabate E, Alvarez J, Vera A, Posadas S, Jurado A, Blanca M. Improvement of toxic epidermal necrolysis after the early administration of a single high dose of intravenous immunoglobulin. Ann Allergy Asthma Immunol. 2003;91(1):86-91.
48. Zawodniak A, Lochmatter P, Yerly D, Kawabata T, Lerch M, Yawalkar N, Pichler WJ. In vitro detection of cytotoxic T and NK cells in peripheral blood of patients with various drug-induced skin diseases. Allergy. 2010;65(3):376-84.
49. Nishio D, Izu K, Kabashima K, Tokura Y. T cell populations propagating in the peripheral blood of patients with drug eruptions. J Dermatol Sci. 2007;48(1):25-33.
50. Tsuge I, Okumura A, Kondo Y, Itomi S, Kakami M, Kawamura M, Nakajima Y, Komatsubara R, Urisu A. Allergen-specific T-cell response in patients with phenytoin hypersensitivity; simultaneous analysis of proliferation and cytokine production by carboxyfluorescein succinimidyl ester (CFSE) dilution assay. Allergol Int. 2007;56(2):149-55.
51. Pichler WJ, Yawalkar N, Britschgi M, Depta J, Strasser I, Schmid S, Kuechler P, Naisbitt D. Cellular and molecular pathophysiology of cutaneous drug reactions. Am J Clin Dermatol. 2002;3(4):229-38.
52. Schaerli P, Britschgi M, Keller M, Steiner UC, Steinmann LS, Moser B, Pichler WJ. Characterization of human T cells that regulate neutrophilic skin inflammation. J Immunol. 2004;173(3):2151-8.
53. Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP)--a clinical reaction pattern. J Cutan Pathol. 2001;28(3):113-9.
54. Britschgi M, Pichler WJ. Acute generalized exanthematous pustulosis, a clue to neutrophil-mediated inflammatory processes orchestrated by T cells. Curr Opin Allergy Clin Immunol. 2002;2(4):325-31.
55. Halevy S. Acute generalized exanthematous pustulosis. Curr Opin Allergy Clin Immunol. 2009;9(4):322-8.
56. Padial MA, Álvarez-Ferreira J, Tapia B, Blanco R, Manas C, Blanca M, Bellon T. Acute generalized exanthematous pustulosis associated with pseudoephedrine. Br J Dermatol. 2004;150(1):139-42.
57. Mizukawa Y, Shiohara T. Fixed drug eruption: a prototypic disorder mediated by effector memory T cells. Curr Allergy Asthma Rep. 2009;9(1):71-7.
58. Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol. 2009;9(4):316-21.
59. Wu Y, Farrell J, Pirmohamed M, Park BK, Naisbitt DJ. Generation and characterization of antigen-specific CD4+, CD8+, and CD4+CD8+ T-cell clones from patients with carbamazepine hypersensitivity. J Allergy Clin Immunol. 2007;119(4):973-81.
60. Mayorga C, Pena RR, Blanca-López N, López S, Martín E, Torres MJ. Monitoring the acute phase response in non-immediate allergic drug reactions. Curr Opin Allergy Clin Immunol. 2006;6(4):249-57.
61. Fernández TD, Mayorga C, Torres MJ, Cornejo-García JA, López S, Chaves P, Rondon C, Blanca M. Cytokine and chemokine expression in the skin from patients with maculopapular exanthema to drugs. Allergy. 2008;63(6):712-9.
62. Homey B, Alenius H, Muller A, Soto H, Bowman EP, Yuan W, McEvoy L, Lauerma AI, Assmann T, Bunemann E, Lehto M, Wolff H, Yen D, Marxhausen H, To W, Sedgwick J, Ruzicka T, Lehmann P, Zlotnik A. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med. 2002;8(2):157-65.
63. Flier J, Boorsma DM, van Beek PJ, Nieboer C, Stoof TJ, Willemze R, Tensen CP. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol. 2001;194(4):398-405.
64. Yawalkar N, Egli F, Hari Y, Nievergelt H, Braathen LR, Pichler WJ. Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Clin Exp Allergy. 2000;30(6):847-55.
65. Teraki Y, Moriya N, Shiohara T. Drug-induced expression of intercellular adhesion molecule-1 on lesional keratinocytes in fixed drug eruption. Am J Pathol. 1994;145(3):550-60.
66. Thong BY, Mirakian R, Castells M, Pichler W, Romano A, Bonadonna P, Diana D, Kowalski M, Yanez A, Lleonart R, Sanchez-Borges M, Demoly P. A world allergy organization international survey on diagnostic procedures and therapies in drug allergy/hypersensitivity. World Allergy Organ J. 2011;4(12):257-70.
67. Hanafusa T, Azukizawa H, Matsumura S, Katayama I. The predominant drug-specific T-cell population may switch from cytotoxic T cells to regulatory T cells during the course of anticonvulsant-induced hypersensitivity. J Dermatol Sci. 2012;65(3):213-9.
68. Luque I, Leyva L, Jose Torres M, Rosal M, Mayorga C, Segura JM, Blanca M, Juarez C. In vitro T-cell responses to beta-lactam drugs in immediate and nonimmediate allergic reactions. Allergy. 2001;56(7):611-8.
69. Naisbitt DJ, Britschgi M, Wong G, Farrell J, Depta JP, Chadwick DW, Pichler WJ, Pirmohamed M, Park BK. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol. 2003;63(3):732-41.
70. Naisbitt DJ, Farrell J, Wong G, Depta JP, Dodd CC, Hopkins JE, Gibney CA, Chadwick DW, Pichler WJ, Pirmohamed M, Park BK. Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol. 2003;111(6):1393-403.
71. Nyfeler B, Pichler WJ. The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity. Clin Exp Allergy. 1997;27(2):175-81.
72. Schnyder B, Pichler WJ. Skin and laboratory tests in amoxicillin-and penicillin-induced morbilliform skin eruption. Clin Exp Allergy. 2000;30(4):590-5.
73. Yawalkar N, Shrikhande M, Hari Y, Nievergelt H, Braathen LR, Pichler WJ. Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions. J Allergy Clin Immunol. 2000;106(6):1171-6.
74. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy. 2004;59(8):809-20.
75. Elzagallaai AA, Knowles SR, Rieder MJ, Bend JR, Shear NH, Koren G. In vitro testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review. Mol Diagn Ther. 2009;13(5):313-30.
76. Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy. 2007;62(12):1439-44.
77. Beeler A, Pichler WJ. In vitro test of T-Cell-Mediated hypersensitivity. In: Pichler WJ, editor. Drug Hypersensitivity. Karger; 2007: Basel. p. 380-390.
78. Rodriguez-Pena R, Lopez S, Mayorga C, Antunez C, Fernandez TD, Torres MJ, Blanca M. Potential involvement of dendritic cells in delayed-type hypersensitivity reactions to beta-lactams. J Allergy Clin Immunol. 2006;118(4):949-56.
79. Chaves P, Torres MJ, Aranda A, López S, Cantó G, Blanca M, Mayorga C. Natural killer-dendritic cell interaction in lymphocyte responses in hypersensitivity reactions to betalactams. Allergy. 2010;65(12):1600-8.
80. López S, Torres MJ, Rodríguez-Pena R, Blanca-López N, Fernández TD, Antúnez C, Cantó G, de Luque V, Mayorga C. Lymphocyte proliferation response in patients with delayed hypersensitivity reactions to heparins. Br J Dermatol. 2009;160(2):259-65.
81. Castrejon JL, Berry N, El-Ghaiesh S, Gerber B, Pichler WJ, Park BK, Naisbitt DJ. Stimulation of human T cells with sulfonamides and sulfonamide metabolites. J Allergy Clin Immunol. 2010;125(2):411-418 e4.
82. Gómez E P-CG, Castell JV, Torres MJ, Blanca M, Mayorga C. Effect of metabolising cell system in lymphocyte transformation test to evaluate non immediate reaction to anticonvulsants. In EAACI. 2011: Istanbul.
83. Porebski G, Gschwend-Zawodniak A, Pichler WJ. In vitro diagnosis of T cell-mediated drug allergy. Clin Exp Allergy. 2011;41(4):461-70.
84. Czerkinsky C, Moldoveanu Z, Mestecky J, Nilsson LA, Ouchterlony O. A novel two colour ELISPOT assay. I. Simultaneous detection of distinct types of antibody-secreting cells. J Immunol Methods. 1988;115(1):31-7.
85. Sanz ML, Mayorga C, Martínez-Aranguren R, Gamboa PM. Drug Hypersensitivity. In Intech 2012:261-278.
86. Tanvarasethee B, Buranapraditkun S, Klaewsongkram J. The potential of using enzyme-linked immunospot to diagnose cephalosporin-induced maculopapular exanthems. Acta Derm Venereol. 2013;93(1):66-9.
87. Maino VC, Suni MA, Ruitenberg JJ. Rapid flow cytometric method for measuring lymphocyte subset activation. Cytometry. 1995;20(2):127-33.
88. Torres MJ, Corzo JL, Leyva L, Mayorga C, García-Martín FJ, Antúnez C, Posadas S, Jurado A, Blanca M. Differences in the immunological responses in drug-and virus-induced cutaneous reactions in children. Blood Cells Mol Dis. 2003;30(1):124-31.
89. Beeler A, Zaccaria L, Kawabata T, Gerber BO, Pichler WJ. CD69 upregulation on T cells as an in vitro marker for delayed-type drug hypersensitivity. Allergy. 2008;63(2):181-8.
90. Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology. 2005;209(2):123-9.
91. Martín M, Wurpts G, Ott H, Baron JM, Erdmann S, Merk HF, Sachs B. In vitro detection and characterization of drug hypersensitivity using flow cytometry. Allergy. 2010;65(1):32-9.
92. Padial A, Posadas S, Álvarez J, Torres MJ, Álvarez JA, Mayorga C, Blanca M. Nonimmediate reactions to systemic corticosteroids suggest an immunological mechanism. Allergy. 2005;60(5):665-70.
93. Sachs B, Erdmann S, Malte Baron J, Neis M, al Masaoudi T, Merk HF. Determination of interleukin-5 secretion from drug-specific activated ex vivo peripheral blood mononuclear cells as a test system for the in vitro detection of drug sensitization. Clin Exp Allergy. 2002;32(5):736-44.
94. Yoshimura T, Hamaguchi E, Usami E, Nakashima K, Kawaguchi M, Suzuki N, Okamoto Y, Nakao T, Yamazaki F. Increased in vitro release of interferon-gamma from ampicillin-stimulated peripheral blood mononuclear cells in Stevens-Johnson syndrome. Biol Pharm Bull. 2004;27(6):929-31.
95. Ju C. Immunological mechanisms of drug-induced liver injury. Curr Opin Drug Discov Devel. 2005;8(1):38-43.
96. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov. 2005;4(6):489-99.
97. Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology. 2006;43(3):618-31.
98. El-Ghaiesh S, Sanderson JP, Farrell J, Lavergne SN, Syn WK, Pirmohamed M, Park BK, Naisbitt DJ. Characterization of drug-specific lymphocyte responses in a patient with drug-induced liver injury. J Allergy Clin Immunol. 2011;128(3):680-3.
99. Straumann A, Bauer M, Pichler WJ, Pirovino M. Acute pancreatitis due to pyritinol: an immune-mediated phenomenon. Gastroenterology. 1998;115(2):452-4.
100. Saito M, Yagi M, Uno K, Takanaka K. Comparative study of the usefulness of the drug-induced lymphocyte stimulation test and the leukocyte migration test in drug allergies. Biol Pharm Bull. 2008;31(2):299-304.
101. Tomioka R, King TE, Jr. Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid lung disease. Am J Respir Crit Care Med. 1997;155(3):1011-20.
102. Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res. 2012;13:39.
103. Kardaun SH, de Monchy JG. Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test. J Am Acad Dermatol. 2006;55(2 Suppl):S21-3.
104. Mori H, Yamanaka K, Kaketa M, Tamada K, Hakamada A, Isoda K, Yamanishi K, Mizutani H. Drug eruption caused by azathioprine: value of using the drug-induced lymphocytes stimulation test for diagnosis. J Dermatol. 2004;31(9):731-6.
105. Berger D, Pichler W, Savic S, Schoenenberger R, Borer H. [Fever, pneumonia and eosinophilia]. Praxis (Bern 1994). 2007;96(40):1543-7. German
106. Matsuno O, Okubo T, Hiroshige S, Takenaka R, Ono E, Ueno T, Nureki S, Ando M, Miyazaki E, Kumamoto T. Drug-induced lymphocyte stimulation test is not useful for the diagnosis of drug-induced pneumonia. Tohoku J Exp Med. 2007;212(1):49-53.
107. Yasui M, Fujimura M. The significance of DLST and drug provocation test. Jpn J Chest Dis. 2003;62:885-91.
108. Toyoshima M, Sato A, Hayakawa H, Taniguchi M, Imokawa S, Chida K. A clinical study of minocycline-induced pneumonitis. Intern Med. 1996;35(3):176-9.
109. Ingham E, Turnbull L, Kearney JN. The effects of minocycline and tetracycline on the mitotic response of human peripheral blood-lymphocytes. J Antimicrob Chemother. 1991;27(5):607-17.
110. Thong YH, Ferrante A. Inhibition of mitogen-induced human lymphocyte proliferative responses by tetracycline analogues. Clin Exp Immunol. 1979;35(3):443-6.
111. Afane M, Ramos F, Chassagne J, Dubost JJ, Galtier B, Sauvezie B. Discrepancy between 3H-thymidine uptake and cell cycle studies in stimulated lymphocyte cultures treated with methotrexate. Clin Exp Rheumatol. 1989;7(6):603-8.
112. Hirata S, Hattori N, Kumagai K, Haruta Y, Yokoyama A, Kohno N. Lymphocyte transformation test is not helpful for the diagnosis of methotrexate-induced pneumonitis in patients with rheumatoid arthritis. Clin Chim Acta. 2009;407(1-2):25-9.
113. Spanou Z, Keller M, Britschgi M, Yawalkar N, Fehr T, Neuweiler J, Gugger M, Mohaupt M, Pichler WJ. Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. J Am Soc Nephrol. 2006;17(10):2919-27.